Acute Kidney Injury Following Paediatric Cardiac Surgery (p-MiVAKI)

January 29, 2020 updated by: University of Leicester

A Feasibility Study to Consider the Role of Microvesicles (MV) and MV Derived microRNA (miRNA) in Acute Kidney Injury (AKI) Following Paediatric Cardiac Surgery: p-MiVAKI Study

Acute kidney injury (AKI) complicates over 50% of cardiac surgical procedures in children where it increases morbidity and the use of healthcare resources. The pathogenesis of AKI is poorly understood, current diagnostic tests lack specificity and sensitivity, and there is no effective treatment. Improving outcomes in patients at risk of AKI has recently been defined as a National Health Service priority. The investigators are currently undertaking a program of work that is evaluating the role of plasma-derived microvesicles (MV) and MV associated microRNAs (miRNA) as diagnostic biomarkers or therapeutic targets in cardiac surgery patients at risk of developing AKI. Preliminary results indicate that these biomarkers may have clinical utility in adults. An important consideration is whether these biomarkers also have utility in children undergoing cardiac surgery. Measurement of MV at serial time points in children presents ethical challenges related to conducting clinical research in critically ill subjects. It also presents technical challenges related to the very small volumes of blood that may be sampled safely from babies and infants undergoing surgery. The aim of the study is to provide estimates of the perioperative variance of MV concentrations in 24 children undergoing cardiac surgery, as well as the frequency of AKI and other adverse events, protocol adherence and recruitment rates. This will assist with the design of a subsequent prospective observational study that will consider the role of MV/miRNA in children undergoing cardiac surgery.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is a prospective, single-centre observational feasibility study that will measure changes in MV signalling and their relationship to inflammatory responses after cardiac surgery in children.

The investigators primary hypothesis is that inflammatory renal injury following paediatric cardiac surgery is regulated by circulating MV and more specifically MV associated miRNA.

The investigators secondary hypotheses are:

  1. MV derived signals will differ in cyanotic patients, a patient group at significantly increased risk for AKI.
  2. MV subsets and/or MV derived miRNA may act as novel diagnostic biomarkers for AKI.

To assist with the design of a prospective observational study that will test these hypotheses the investigators propose to undertake a feasibility study in 24 children. The objectives of this feasibility study are:

A.To establish the numbers of patients that are eligible for enrolment in the study, the number recruited to the study, and their clinical and demographic characteristics.

B.To determine the proportion of consented patients who develop AKI following cardiac surgery.

C.To measure perioperative changes in MV subgroups and MV associated miRNA, as well as platelet and monocyte activation, and the variance of these measures.

D.To establish protocol adherence, with respect to the adequacy and timing of the blood samples that are taken and the calculation of creatinine clearance perioperatively.

Study Type

Observational

Enrollment (Anticipated)

24

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Leicestershire
      • Leicester, Leicestershire, United Kingdom, LE3 9QP
        • Glenfield Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 17 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Children undergoing cardiac surgery in a tertiary academic cardiac surgery unit

Description

Inclusion Criteria:

  1. Patients undergoing congenital heart operations with cardio-pulmonary bypass.
  2. Patients aged ≤ 17 years of age.
  3. Patients with a body weight > 2kg.

Exclusion Criteria:

  1. Patients with pre-existing inflammatory state: sepsis undergoing treatment, acute kidney injury within 5 days or chronic inflammatory disease.
  2. Emergency (operation before the beginning of the next working day after decision to operate) or salvage procedure (patients requiring cardiopulmonary resuscitation - external cardiac massage - en route to the operating theatre or prior to induction of anaesthesia. This does not include cardiopulmonary resuscitation following induction of anaesthesia)
  3. Patients where Extracorporeal Membrane Oxygenation (ECMO) support is required.
  4. Patients likely to require ECMO postoperatively.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Children undergoing cardiac surgery
Paediatric patients (<17 years with a body weight >2000g) undergoing cardiac surgery for congenital heart disease with extracorporeal circulation
cardiac surgery with extracorporeal circulation for congenital heart disease

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change from baseline in annexin V positive microvesicles
Time Frame: Pre-operatively, 6-12 hrs post-op and 24 hrs post-op
Mean plasma concentration of Annexin V positive MV and the concentration variance in plasma from arterial blood samples collected prior to anaesthetic induction, and at 6-12 and 24 hours postoperatively.
Pre-operatively, 6-12 hrs post-op and 24 hrs post-op
change from baseline in microvesicles derived miRNA
Time Frame: Pre-operatively, 6-12 hrs post-op and 24 hrs post-op
Mean plasma concentration of MV derived miRNA and the concentration variance in plasma from arterial blood samples collected prior to anaesthetic induction, and at 6-12 and 24 hours postoperatively.
Pre-operatively, 6-12 hrs post-op and 24 hrs post-op

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Eligibility
Time Frame: pre-operatively
Since this is a feasibility study, the investigators will evaluate the rate of patients who are eligible among the whole population of screened patients
pre-operatively
Recruitment
Time Frame: preoperatively
Since this is a feasibility study, the investigators will evaluate the rate of patients who will be recruited among the whole population of approached patients
preoperatively
Protocol non-adherence
Time Frame: Pre-operatively, 6-12 hrs post-op and 24 hrs post-op
Since this is a feasibility study, the investigators will evaluate protocol non-adherence defined as the failure to obtain the specified blood volume or urine sample required for analysis at the required time.
Pre-operatively, 6-12 hrs post-op and 24 hrs post-op
Acute Kidney Injury
Time Frame: preoperatively, postoperatively every day until day 7
Acute kidney injury defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria
preoperatively, postoperatively every day until day 7
Variation in Renal inflammation
Time Frame: Pre-operatively, 6-12 hrs post-op and 24 hrs post-op
Variation in Renal inflammation will be determined by variation in values of urine Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Liver type- Fatty Acid Binding Protein (L-FABP) and urinary nitric oxide bioavailability .
Pre-operatively, 6-12 hrs post-op and 24 hrs post-op
Incidence of Acute Lung Injury - Low Cardiac Output
Time Frame: preoperatively, postoperatively every day until day 7
Acute Lung Injury (PaO2/FiO2<300mmHg)
preoperatively, postoperatively every day until day 7
Incidence of Low Cardiac Output
Time Frame: preoperatively, postoperatively every day until day 7
Low Cardiac Output (the use of two or more inotropes)
preoperatively, postoperatively every day until day 7
Variation in pro-coagulant potential of microvesicles
Time Frame: Pre-operatively, 6-12 hrs post-op and 24 hrs post-op
This is a measure of MV tissue factor expression and indicates the likely pro-inflammatory effect of the MV.
Pre-operatively, 6-12 hrs post-op and 24 hrs post-op
Variations in sources of microvesicles
Time Frame: Pre-operatively, 6 - 12 hrs post-op and 24 hrs post-op
Sources of MV: platelet, endothelial and monocyte activation will be determined by flow cytometry.
Pre-operatively, 6 - 12 hrs post-op and 24 hrs post-op
Variations in systemic inflammatory cytokine response
Time Frame: Pre-operatively, 6 - 12 hrs post-op and 24 hrs post-op
The systemic inflammatory cytokine response will be quantified by measurement of serum interleukin-8, interleukin-6, tumor necrosis factor -α, monocyte chemotactic protein -1, monocyte chemotactic protein -3, intercellular adhesion molecule, E-selectin.
Pre-operatively, 6 - 12 hrs post-op and 24 hrs post-op

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2014

Primary Completion (Actual)

May 1, 2017

Study Completion (Actual)

May 1, 2017

Study Registration Dates

First Submitted

September 2, 2014

First Submitted That Met QC Criteria

November 12, 2014

First Posted (Estimate)

November 13, 2014

Study Record Updates

Last Update Posted (Actual)

January 30, 2020

Last Update Submitted That Met QC Criteria

January 29, 2020

Last Verified

May 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • 0463
  • 14/EM/1136 (Other Identifier: East Midlands - Nottingham 1 Research Ethics Committee)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Kidney Injury

Clinical Trials on cardiac surgery

3
Subscribe